Bio Green Med Solution (BGMS) Cash & Equivalents (2010 - 2026)

Bio Green Med Solution (BGMS) has reported Cash & Equivalents for 17 consecutive years, with $3.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 4.35% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (down 4.35% YoY), while the FY2025 annual figure was $3.5 million, up 11.73% from the prior year.
• Cash & Equivalents declined to $3.3 million in Q1 2026 per BGMS's latest filing, from $3.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $29.6 million in Q1 2022 and bottomed at $75000.0 in Q4 2023.
• Historically, Cash & Equivalents has averaged $9.5 million across 5 years, with a median of $4.3 million in 2025.
• Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 99.59% — and 2024, when it soared 4082.67%.
• Bio Green Med Solution's Cash & Equivalents stood at $18.3 million in 2022, then plunged by 99.59% to $75000.0 in 2023, then jumped by 4082.67% to $3.1 million in 2024, then gained by 11.73% to $3.5 million in 2025, then dropped by 5.85% to $3.3 million in 2026.
• Business Quant data shows BGMS's Cash & Equivalents at $3.3 million in Q1 2026, $3.5 million in Q4 2025, and $3.8 million in Q3 2025.